FAA Updates Mental Wellness Procedures, Lets Pilots on Antidepressants See Any AME and Cuts Waiting Period to 60 Days
Why It MattersMoving antidepressant certification into ordinary AME offices lowers the cost and delay of seeking treatment, which tests whether easier access leads more crews to disclose and manage conditions earlier.
What happened
Recent changes to the Federal Aviation Administration's aeromedical mental wellness policies expand access to aviation medical examiners (AMEs), ease certain antidepressant medication requirements and add resources to help pilots navigate medical certification. The National Business Aviation Association (NBAA) welcomed the update on Nov. 20, 2026.

The update eliminates the requirement for a pilot taking an FAA-accepted antidepressant to consult a human intervention motivation study (HIMS) AME for initial or follow-up certification. Affected pilots may now work with any AME. Laila Stein, NBAA flight operations manager and the association's aeromedical lead, said the change expands the number of AMEs who can work with aviators on antidepressants nearly tenfold, giving pilots more choice and potentially reducing costs, travel and delays. She cautioned that a new AME may not have the same experience with mental wellness.
Other changes include a shorter waiting period before reapplying for certification after discontinuing antidepressant medication, reduced from 90 days to 60. Previous selective serotonin reuptake inhibitor decision pathways have been incorporated into diagnosis-based disposition tables, consolidating existing requirements and documentation. Under certain circumstances, pilots changing antidepressant dosages may temporarily ground themselves and return to flying without additional FAA notification, subject to the terms of their authorization.
Mark Larsen, CAM, NBAA director of safety and flight operations, noted that pilots can hold such conversations with their AME ahead of the formal medical exam, including how to complete MedXpress. He said having all required information available at the exam can significantly affect how quickly the AME or the FAA processes an application, especially when the AME cannot issue the certificate directly.
Industry impact & what to watch
For a business-aviation crew, the practical barrier to treatment has often been the certification process around it rather than the medication itself. Restricting antidepressant cases to a narrow pool of specialist examiners adds travel, cost and scheduling friction, and each of those pushes pilots toward delaying care or staying silent. Opening the work to any AME, shortening the reapplication wait and consolidating documentation all lower that friction at the system level.
The trade-off Stein points to is real: a general AME may have less experience with mental wellness cases than a HIMS-trained one, so quality of handling can vary by examiner. How well pilots prepare in advance, including the pre-exam conversations Larsen describes and complete MedXpress submissions, will shape whether the wider access shortens processing or simply moves delays elsewhere.
NBAA said it continues to advocate for aeromedical policies that encourage early treatment of mental health and other medical concerns while protecting aviation safety. The measure of this change will be whether certification outcomes and processing times for these pilots hold up as the larger examiner pool takes on cases.

















































